Switch theme
Sign up to access all valuation multiples
Oxurion NV is a clinical-stage biopharmaceutical company developing next-generation standard-of-care ophthalmic therapies, which are designed to improve and preserve vision in patients with retinal disorders including Geographic Atrophy (GA). The Group’s research and development facilities are located in Belgium. The Company is engaged in the development of drugs to treat blindness diseases.
2006
11
Last FY Revenue $3K
Last FY EBITDA $0.3M
$12.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Oxurion achieved revenue of $3K and an EBITDA of $0.3M.
Oxurion expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Oxurion valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $3K | XXX | XXX | XXX |
| Gross Profit | XXX | -$45K | XXX | XXX | XXX |
| Gross Margin | XXX | -1333% | XXX | XXX | XXX |
| EBITDA | XXX | $0.3M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 9267% | XXX | XXX | XXX |
| EBIT | XXX | $0.4M | XXX | XXX | XXX |
| EBIT Margin | XXX | 12733% | XXX | XXX | XXX |
| Net Profit | XXX | $0.1M | XXX | XXX | XXX |
| Net Margin | XXX | 3967% | XXX | XXX | XXX |
| Net Debt | XXX | $12.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Oxurion's stock price is EUR 0 (or $0).
Oxurion has current market cap of EUR 0.3M (or $0.3M), and EV of EUR 11.2M (or $12.6M).
See Oxurion trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12.6M | $0.3M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Oxurion has market cap of $0.3M and EV of $12.6M.
Oxurion's trades at 3726.6x EV/Revenue multiple, and 40.2x EV/EBITDA.
Equity research analysts estimate Oxurion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Oxurion's P/E ratio is not available.
See valuation multiples for Oxurion and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $0.3M | XXX | $0.3M | XXX | XXX | XXX |
| EV (current) | $12.6M | XXX | $12.6M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 3726.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 40.2x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 29.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 2.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -5.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOxurion's revenue per employee in the last FY averaged $0K, while opex per employee averaged -$43K for the same period.
Oxurion's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Oxurion's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Oxurion and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 9267% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | -$43K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 333% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 45067% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | -14067% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oxurion acquired XXX companies to date.
Last acquisition by Oxurion was XXXXXXXX, XXXXX XXXXX XXXXXX . Oxurion acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Oxurion founded? | Oxurion was founded in 2006. |
| Where is Oxurion headquartered? | Oxurion is headquartered in Belgium. |
| How many employees does Oxurion have? | As of today, Oxurion has 11 employees. |
| Who is the CEO of Oxurion? | Oxurion's CEO is Mr. Pascal Ghoson. |
| Is Oxurion publicy listed? | Yes, Oxurion is a public company listed on BRU. |
| What is the stock symbol of Oxurion? | Oxurion trades under OXUR ticker. |
| When did Oxurion go public? | Oxurion went public in 2006. |
| Who are competitors of Oxurion? | Similar companies to Oxurion include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Oxurion? | Oxurion's current market cap is $0.3M |
| Is Oxurion profitable? | Yes, Oxurion is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
